Impact on response to therapy

There has been considerable debate about the effect non-B subtype polymorphisms and differing resistance pathways may have on response to therapy and the likelihood of resistance.

Several studies have found that different resistance pathways do not undermine the benefits of antiretroviral therapy. One early randomised study found no significant difference in virologic response at weeks 24 or 48 when comparing children with B and non-B subtypes.1

In a pooled analysis of data from two large UK databases, incorporating results from over 2100 patients, researchers found that subtypes B, C, A, D, and CRF_AG, patients were equally likely to suppress viral load and recover CD4 cells once highly active antiretroviral treatment was begun.ref] 

References

  1. Pillay D et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186: 617-625, 2002
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.